Efung Capital

Novlead Biotech is a developer and manufacturer of medical devices specializing in cardiopulmonary, respiratory, and anti-infection applications. The company leverages technological innovations, particularly the medical application of nitric oxide, to address conditions such as pulmonary hypertension and infectious diseases. By focusing on these critical areas, Novlead Biotech aims to enhance treatment efficiency in hospitals and improve the quality of life for patients. Through its advancements, the company contributes to safer and healthier outcomes in healthcare.

Shineyo Medical is a company that specializes in developing minimally invasive treatment devices for cardiovascular interventions, with a particular focus on electrophysiology and peripheral interventions. The company is dedicated to addressing conditions such as atrial fibrillation and varicose veins. It offers a venous closure system designed to treat varicose veins effectively by using active devices, interventional catheters, and implant materials. This system utilizes vein sealant to permanently close superficial veins, ensuring significant treatment outcomes for patients. Shineyo Medical aims to establish itself as a leading domestic provider of these innovative solutions.

Meichuang Medical is an innovative medical device company that focuses on the R&D, manufacturing and commercialization of high-end medical devices in the fields of peripheral vascular intervention, tumor intervention, and hemodialysis access maintenance

Huiguan Biology is a developer of super-resolution microscopes for in vivo drug screening.

CATUG Biotechnology specializes in the development and application of advanced biomedical technologies, particularly in the fields of gene therapy and nucleic acid drugs. The company offers comprehensive contract development and manufacturing organization (CDMO) services, addressing the entire industry chain from research and development to clinical applications and industrialization. CATUG operates R&D centers and industrialization bases located in Suzhou and Wuhan, facilitating its focus on drug research and production services.

Pregis New Materials specializes in cold chain technology, focusing on solutions that ensure the safe transportation of biomedical products. The company develops innovative cold-chain logistics products that incorporate dual carbon and temperature control solutions. Utilizing Internet of Things (IoT) technology, Pregis enables real-time temperature monitoring and control, enhancing the reliability of product transport. Additionally, the company employs durable temperature control materials, which support clients in efficiently and safely delivering sensitive goods.

Turno is a fintech startup that provides electric vehicle solutions for operators and owners. It helps commercial vehicle operators make the switch to EVs. Turno accomplishes this by offering a diverse range of vehicles from partner OEMs, affordable financing, and battery value guarantees to ensure the best possible return on investment for EV owners. Turno's mission in India is to convert gasoline miles to electric miles. The startup sells EVs manufactured by various brands both online and in physical stores, as well as providing financing options and buying back used batteries.

Huayuan Regenerative Medicine is the manufacture of implantable bioartificial organs. Huayuan Regenerative Medicine is committed to the research and development, production, and sales of clinical grade stem cells, biological tissue engineering products, and biomanufacturing. Their clinical products include urinary kidney precursor cells, dialysis equipment, and a biosynthetic artificial pancreas.

Nanjing IASO Biotherapeutics is a clinical stage biotechnology company established in 2017 and located in Nanjing, China. The company specializes in the discovery, development, and commercialization of innovative therapies aimed at treating cancer. IASO Biotherapeutics is particularly focused on engineered autologous and allogenic T cell therapies, which are designed to enhance the immune system's capability to identify and eliminate cancer cells. Through its research and development efforts, the company aims to provide effective cancer treatments that leverage the body's own immune response.

Raynovent is an innovative biotech company focused on researching and developing new drugs for liver and respiratory diseases. The company aims to create effective treatment therapies for patients suffering from viral and infectious illnesses in these areas. Through its expertise in pharmaceutical biotechnology consulting and technology transfer, Raynovent supports healthcare professionals in diagnosing and treating infectious diseases more effectively.

JGene Biotechnology is a research and development biotechnology company dedicated to the research and development of universal CAR-NK/T products from iPS. It is hoped that the large-scale production of CAR-NK/T from iPS will provide cancer patients with spot-type, price-friendly, and affordable new immune cell therapy products. Recently received angel round investment.

Maijing Gene is a gene detection technology company that specializes in R&D, production, and sales of molecular diagnostic products. It is also committed to promoting the application of second-generation high-throughput sequencing technology in the field of precision medicine. Maijing Gene was established in 2015 and is based in Guangzhou, China.

JSD provides medical equipment for hospitals. They provides substitution machines for the medical industry. For inquiries, telephone and email are used.

CellOrigin Biotech specializes in the development of innovative therapeutics using induced pluripotent stem cells (iPSCs) to create innate immune cells. The company is dedicated to advancing immune cell technology aimed at treating solid tumors. Its research focuses on the generation of gene-manipulated, clinically applicable iPSCs and the establishment of a clinical iPSC bank. Additionally, CellOrigin Biotech is developing an efficient platform for differentiating iPSCs into mature stem cells, which enhances their potential for therapeutic applications. Through these efforts, the company aims to contribute significantly to the field of cancer treatment.

Westlake Omi combines proteomic big data with artificial intelligence, mass spectrometry-based biological sample digitization technology.

Atom Bioscience is a clinical-stage biotechnology company focused on developing innovative therapies for inflammatory and metabolic diseases. The company concentrates on addressing conditions such as chronic gout, non-alcoholic steatohepatitis, diabetes, and colon cancers. By targeting the underlying mechanisms of metabolism and inflammation, Atom Bioscience aims to provide patients with more effective treatment options for these complex health issues.

Cloudbreak Therapeutics LLC is a clinical-stage biotechnology company based in Irvine, California, focused on developing ocular drugs for conditions such as glaucoma and pterygium. Founded in 2015, the company utilizes a capital-efficient business model that repurposes approved systemic drugs for ocular delivery. By prioritizing the rapid advancement of drug candidates through proof-of-concept Phase II clinical trials, Cloudbreak Therapeutics aims to out-license global rights for Phase III trials, product registration, and commercialization. The company strategically collaborates with contract research organizations to manage non-clinical, chemistry, manufacturing, and clinical development, thus maximizing its resources for effective drug development.

Kind Pharmaceutical is a clinical-stage biopharmaceutical company that focuses on the discovery and development of anemia drugs. The company was founded in 2013 and is headquartered in Redwood City, California, United States.

BioInno is a China-based company that specializes in biopharmaceutical contract development and manufacturing organization (CDMO) services. It focuses on process development and Good Manufacturing Practice (GMP) production for biotechnology and pharmaceutical companies seeking to introduce protein, cell therapy, and gene therapy drugs to both the Chinese and global markets. By offering comprehensive outsourcing solutions, BioInno supports clients in the complex development and production processes necessary for bringing innovative therapies to market.

CirCode Bio is an innovative biotechnology company focusing on the development of circular RNA nucleic acid drugs.

JGene Biotechnology is a research and development biotechnology company dedicated to the research and development of universal CAR-NK/T products from iPS. It is hoped that the large-scale production of CAR-NK/T from iPS will provide cancer patients with spot-type, price-friendly, and affordable new immune cell therapy products. Recently received angel round investment.

TriArm Therapeutics is a cell therapy company established by Panacea Venture, with research and development operations in Germany, the United States, and the Greater China region. The company specializes in the research and clinical development of CD19 CAR-T products, utilizing non-viral gene transfer technology. This innovative approach significantly lowers both the cost and preparation time associated with cell therapy products, ultimately aiming to enhance therapeutic outcomes for cancer patients.

Genuine Biotech manufactures drugs for the treatment of viral infection, tumors, and cerebrovascular disorders.

Gensciences is engaged in the research and development of biopharmaceutical technology, focusing on innovative drugs, particularly long-acting recombinant proteins. The company aims to address medical conditions such as hemophilia, metabolic diseases, and tumors. Gensciences is dedicated to producing high-safety and high-efficacy treatments, striving for a high success rate in its drug development initiatives. Through continuous innovation, the company seeks to make significant contributions to the global biopharmaceutical landscape while benefiting patient groups in need of advanced therapeutic options.

Raynovent is an innovative biotech company focused on researching and developing new drugs for liver and respiratory diseases. The company aims to create effective treatment therapies for patients suffering from viral and infectious illnesses in these areas. Through its expertise in pharmaceutical biotechnology consulting and technology transfer, Raynovent supports healthcare professionals in diagnosing and treating infectious diseases more effectively.

Beijing Biostar Technologies, Ltd. is a biotechnology company based in Beijing, China, founded in 2002. The company specializes in the development of anti-tumor chemotherapy biopharmaceuticals, focusing on the innovation and formulation of small molecule chemical drugs for cancer treatment. Led by a team of Chinese scientists, Biostar engages in biomedical development and technology transfer, offering technical service consulting as part of its operations. The company is recognized for its pioneering work in creating new anti-cancer drugs, including the development of epothilone, and its technologies are considered to be at an internationally advanced level.

3D Medicines is a biopharmaceutical company focused on the research, development, and commercialization of personalized treatments for cancer. By utilizing individuals' genetic information, the company aims to enhance the prevention, diagnosis, and management of cancer as a chronic disease. 3D Medicines specializes in creating differentiated immuno-oncology drugs designed to improve patient outcomes, extending both survival time and quality of life for those affected by cancer. The company generates its revenue exclusively from the Chinese market.

Jifu Medical is a high-tech enterprise dedicated to the research, development, production, sales, and service of advanced medical products for the digestive tract. The company boasts a professional R&D team and an international management platform, having undertaken various technological innovation projects and securing over 100 national patents. Jifu Medical specializes in innovative micro-capsule endoscope technologies, which facilitate non-invasive examinations of the intestinal tract. The company's flagship product line, the "Dasheng" magnetically controlled capsule endoscope system, has been under development for a decade and has received the National Medical Products Administration Class III medical device registration as well as EU CE certification. These products have garnered significant acclaim from medical institutions for their effectiveness in digestive tract diagnosis.

InnerMedical focuses on developing advanced diagnostic and treatment solutions for major diseases, particularly in the areas of cancer, cardiovascular, and cerebrovascular conditions. The company specializes in creating minimally invasive medical imaging devices, including intravascular imaging monitors and high-frequency endoscopic machines. InnerMedical has successfully launched the first domestic endoscopic ultrasonic diagnostic equipment, electronic endoscopes, and a medical image processing software platform. Through its innovative technologies, the company aims to enhance diagnostic accuracy and treatment effectiveness in the clinic, particularly for tumors affecting the digestive and respiratory tracts.

OBiO Technology is a biotechnology company specializing in gene therapy solutions. It offers contract research organization (CRO) services focused on the development of gene therapy vectors, gene function research, and drug target efficacy. The company also provides contract development and manufacturing organization (CDMO) services, which include process development, testing, and IND-CMC pharmaceutical research. Additionally, OBiO Technology supports the production of clinical samples under Good Manufacturing Practices (GMP) for genetic drug research and development. Through its comprehensive offerings, the company aims to advance the field of gene therapy and facilitate the development of innovative therapeutic solutions.

SiBionics is a medtech company based in Shenzhen, China, focused on the research and development of active implantable medical devices and medical artificial intelligence. The company specializes in creating innovative solutions for various health conditions, including retinitis pigmentosa, diabetes, cardiovascular diseases, and gastrointestinal tumors. SiBionics develops artificial intelligence technologies for medical imaging and implantable devices, including retinal electrical stimulators and continuous glucose monitors. Their work also encompasses health management, disease screening, and diagnostics, using approaches such as visual coding, medical imaging AI, and big data analytics to enhance patient care and address chronic diseases. Through these advancements, SiBionics aims to provide cost-effective products that improve long-term monitoring and treatment options in the medical field.

Asieris Pharmaceuticals Co. Ltd. is a Chinese biotechnology company established in 2010, headquartered in Taizhou, China. The company specializes in the research and development of pharmaceutical products aimed at treating tumors and addressing multidrug-resistant infections. Asieris is committed to advancing therapeutic solutions that integrate both diagnosis and treatment, catering to the needs of patients in China and globally. Through its innovative approach, the company seeks to contribute significantly to the fields of oncology and infectious disease management.

Harbour BioMed is a biotechnology company focused on discovering and developing therapeutics for cancer and inflammatory diseases. Established in 2016 with operations in Shanghai, Cambridge, and Rotterdam, the company leverages its proprietary transgenic mouse platforms to generate fully human monoclonal antibodies (H2L2) and heavy chain only antibodies (HCAb), enabling the development of differentiated compounds such as bi-specific and multi-specific antibodies. Harbour BioMed collaborates strategically with various institutions and companies, including The Wistar Institute, WuXi Biologics, and Vir Biotechnology, to advance its pipeline of therapeutics targeting autoimmune diseases, dry eye disease, COVID-19, and other indications.

OBiO Technology is a biotechnology company specializing in gene therapy solutions. It offers contract research organization (CRO) services focused on the development of gene therapy vectors, gene function research, and drug target efficacy. The company also provides contract development and manufacturing organization (CDMO) services, which include process development, testing, and IND-CMC pharmaceutical research. Additionally, OBiO Technology supports the production of clinical samples under Good Manufacturing Practices (GMP) for genetic drug research and development. Through its comprehensive offerings, the company aims to advance the field of gene therapy and facilitate the development of innovative therapeutic solutions.

WeMed is a developer of digital angiography machines designed for use in the clinical fields of radiology and cardiology. The company focuses on enhancing department operations and providing training for medical professionals. Additionally, WeMed implements an international strategy for product research and development, ensuring that its offerings are continuously optimized and upgraded to meet the evolving needs of healthcare providers.

Elicio Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, specializing in the development of amphiphile immunotherapies aimed at treating aggressive cancers. The company leverages its proprietary Amphiphile platform to deliver immunogens directly to the lymphatic system, enhancing the immune response and improving the body’s ability to fight cancer. Elicio's key products include ELI-002, an amphiphile vaccine targeting KRAS gene mutations to prevent recurrence in pancreatic, colorectal, and lung cancers, and ELI-001, which is designed for HPV-driven head and neck cancers. Elicio Therapeutics was founded in 2011 and was previously known as Vedantra Pharmaceuticals before rebranding in 2019. The company focuses on creating innovative immunotherapies for patients with limited treatment options and challenging cancer types.

TriArm Therapeutics is a cell therapy company established by Panacea Venture, with research and development operations in Germany, the United States, and the Greater China region. The company specializes in the research and clinical development of CD19 CAR-T products, utilizing non-viral gene transfer technology. This innovative approach significantly lowers both the cost and preparation time associated with cell therapy products, ultimately aiming to enhance therapeutic outcomes for cancer patients.

Zhongyianke Biotech specializes in the development and provision of human vaccines. The company has successfully launched a flu vaccine and is advancing its research with multiple products currently in clinical trials, including a tetravalent influenza vaccine, a tetravalent meningococcal vaccine, a rabies vaccine, and a rubella vaccine. Zhongyianke holds 14 patents in China, underscoring its commitment to innovation in vaccine technology. With operations centered in Tianjin, the company also maintains a research and development center in Beijing and a production facility in Liaoning Province, enhancing its capacity to contribute to public health through its vaccine offerings.

Tactiva Therapeutics, LLC is a cancer immunotherapy company based in Buffalo, New York, founded in 2016. The company specializes in developing adoptive cell therapy, utilizing a dual T cell receptor approach to enhance treatment efficacy. Its platform includes engineered CD4 and CD8 T cells that not only provide direct anti-tumor activity but also support the function of CD8 T cell-derived effector cells. This innovative approach aims to create a durable supply of T cells that can effectively target and combat life-threatening cancers, enabling healthcare professionals to improve diagnosis and treatment outcomes for patients.

Aridis Pharmaceuticals, Inc. is a late-stage biopharmaceutical company based in San Jose, California, that specializes in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to address life-threatening infections. The company’s lead product candidate, AR-301, is currently undergoing Phase III trials for treating lung infections caused by S. aureus alphatoxin. Additionally, Aridis is advancing several other candidates, including AR-105, a fully human IgG1 mAb in Phase II trials targeting the gram-negative bacterium P. aeruginosa, and AR-101, which is also in Phase II trials for hospital-acquired pneumonia caused by the same pathogen. Other projects in development include AR-401, AR-201, and AR-501, which target various serious infections. Aridis employs proprietary technology platforms to identify and manufacture potent mAbs derived from patients who have successfully overcome infections, enabling the production of therapeutics that are optimized for efficacy without requiring genetic modification. Founded in 2003, Aridis Pharmaceuticals is committed to providing innovative solutions for critical infections.

Lifotronic is a Chinese company specializing in the development, production, and sales of physiotherapy and medical equipment. The company focuses on therapeutic and rehabilitation products, as well as in vitro diagnostic equipment and supporting reagents. Lifotronic's offerings include technologies such as liquid chromatography, nephelometry, and lateral flow immunoassay, which are designed to enhance medical treatment and recovery processes. By providing healthcare providers with innovative solutions, Lifotronic aims to improve patient outcomes and contribute positively to the medical devices sector.

Chipscreen is an integrated biotech company focused on the discovery and development of novel small molecule pharmaceuticals. Established in 2001 as a Sino-foreign joint venture, the company was founded by a group of esteemed Chinese returnees with academic and industrial expertise. Chipscreen employs a proprietary chemical genomics-based discovery platform to create a diverse portfolio of clinical and preclinical programs across various therapeutic areas. The company emphasizes a science-driven approach, strong pipeline development, and expertise in intellectual property and regulatory matters. Its business strategy involves either developing drug candidates independently or in partnership with other organizations throughout the research, preclinical, and clinical stages.

Frontier Biotechnologies Inc. is a commercial-stage biopharmaceutical company based in Nanjing, China, established in 2013. The company specializes in discovering, developing, manufacturing, and commercializing innovative medicines aimed at improving patient health, particularly in the areas of anti-HIV treatment and pain management. Its notable products include Aikening, a long-acting HIV fusion inhibitor, and AB001, a transdermal patch for managing musculoskeletal joint pain. Additionally, Frontier Biotech is developing a combination regimen of Albuvirtide and a monoclonal antibody to combat HIV-1. The company's first product received accelerated approval from the National Medical Product Administration in May 2018, marking a significant milestone in its commercial journey. Currently, two other drug candidates are in Phase I and II clinical trials in both China and the United States. Frontier Biotechnologies combines expertise from various fields, including research and development, management, and marketing, to establish itself as a competitive player in the global market for long-acting HIV treatments and immunotherapy.

Resverlogix Corp. is a late-stage clinical biotechnology company based in Calgary, Canada, focused on developing innovative therapeutics for various severe health conditions. The company's primary product, apabetalone, is a first-in-class small molecule and selective bromodomain and extra-terminal (BET) inhibitor currently undergoing Phase III clinical trials. This drug aims to address cardiovascular diseases, chronic kidney disease, neurodegenerative disorders, and diabetes, among other indications. In addition to apabetalone, Resverlogix is advancing several development programs, including technologies targeting vascular inflammation and Alzheimer's disease. The NexVas platform, which has progressed through initial safety trials, focuses on reducing cardiovascular risk by enhancing ApoA-I levels. Other research initiatives include therapeutics designed for use with medical devices and preclinical projects targeting severe proliferative diseases. Overall, Resverlogix is committed to addressing unmet medical needs in chronic conditions through its diverse pipeline of therapeutic candidates.

Centrexion Therapeutics Corporation is a late clinical-stage biopharmaceutical company based in Boston, Massachusetts, dedicated to developing non-opioid and non-addictive therapies aimed at addressing chronic pain. The company's product pipeline includes CNTX-4975, currently in Phase III trials for moderate to severe knee osteoarthritis pain, and in Phase II trials for Morton’s neuroma and canine osteoarthritis. Additionally, CNTX-0290 is in Phase I trials targeting chronic pain associated with inflammatory, neuropathic, and mixed conditions. Other candidates under development include CNTX-6970, for inflammatory pain, and CNTX-2022, a high-concentration topical gel formulation of lidocaine for various types of pain. CNTX-6016 is also in pre-clinical stages focusing on chronic neuropathic pain. Founded in 2013, Centrexion Therapeutics aims to provide safe and effective solutions for patients suffering from chronic pain conditions.

KBP Biosciences is a biotechnology research and development organization focused on creating innovative therapies for unmet medical needs, particularly in the fields of cardiovascular, respiratory, inflammatory, and autoimmune diseases. The company specializes in the research, development, and commercialization of new medicines, leveraging its expertise in medicinal chemistry and clinical development. By addressing gaps in treatment options, KBP aims to provide healthcare providers with effective solutions for managing conditions that currently lack adequate therapies.

Frontier Biotechnologies Inc. is a commercial-stage biopharmaceutical company based in Nanjing, China, established in 2013. The company specializes in discovering, developing, manufacturing, and commercializing innovative medicines aimed at improving patient health, particularly in the areas of anti-HIV treatment and pain management. Its notable products include Aikening, a long-acting HIV fusion inhibitor, and AB001, a transdermal patch for managing musculoskeletal joint pain. Additionally, Frontier Biotech is developing a combination regimen of Albuvirtide and a monoclonal antibody to combat HIV-1. The company's first product received accelerated approval from the National Medical Product Administration in May 2018, marking a significant milestone in its commercial journey. Currently, two other drug candidates are in Phase I and II clinical trials in both China and the United States. Frontier Biotechnologies combines expertise from various fields, including research and development, management, and marketing, to establish itself as a competitive player in the global market for long-acting HIV treatments and immunotherapy.

Frontier Biotechnologies Inc. is a commercial-stage biopharmaceutical company based in Nanjing, China, established in 2013. The company specializes in discovering, developing, manufacturing, and commercializing innovative medicines aimed at improving patient health, particularly in the areas of anti-HIV treatment and pain management. Its notable products include Aikening, a long-acting HIV fusion inhibitor, and AB001, a transdermal patch for managing musculoskeletal joint pain. Additionally, Frontier Biotech is developing a combination regimen of Albuvirtide and a monoclonal antibody to combat HIV-1. The company's first product received accelerated approval from the National Medical Product Administration in May 2018, marking a significant milestone in its commercial journey. Currently, two other drug candidates are in Phase I and II clinical trials in both China and the United States. Frontier Biotechnologies combines expertise from various fields, including research and development, management, and marketing, to establish itself as a competitive player in the global market for long-acting HIV treatments and immunotherapy.

Ascentage Pharma Group International is a clinical-stage biotechnology company focused on developing novel small-molecule therapies for cancer, hepatitis B virus (HBV), and age-related diseases. Founded in 2009 and headquartered in Suzhou, China, the company has established a diverse pipeline of drug candidates, including HQP1351, a BCR-ABL/KIT inhibitor targeting resistant mutations, and APG-2575, an orally administered Bcl-2 selective inhibitor for hematologic malignancies. Additional candidates include APG-1252, aimed at restoring apoptosis in various solid tumors, and APG-115, which targets the MDM2-p53 interaction in solid tumors and lymphoma. Ascentage Pharma also develops APG-1387 for advanced solid tumors and chronic HBV infection, alongside other therapies for non-small-cell lung carcinoma and chronic lymphocytic leukemia. The company has entered into clinical collaborations to explore innovative treatment combinations, furthering its commitment to addressing challenging diseases in the oncology landscape.

Castdservo provides solutions for the field of robots and intelligent equipment. They serve mobile phone manufacturing, battery manufacturing, metal processing, woodworking engraving, medical treatment, robotics, and other industries.

Shenzhen UniHz Technologies Corporation is a developer of intelligent transportation software and solutions, specializing in urban traffic management. Founded in 2002 and headquartered in Shenzhen, China, the company focuses on research and development in the field of intelligent transportation. It aims to integrate application solutions with product development and manufacturing to enhance traffic management systems. As of November 2020, UniHz operates as a subsidiary of Ping An International Smart City Technology Co., Ltd., further strengthening its capabilities in the smart city sector.

Rainjet is a medical equipment research and development manufacturer. They provide products and services for medical institutions, families, and individuals. The drafting units of the mandatory national pharmaceutical industry standard The psychophysiological lie detector measures, records, and analyses changes in the physiological indicators of the subject.